

EP39

A Hierarchical Approach to Selecting Surrogate Samples for the Evaluation of *In Vitro* Medical Laboratory Tests

This guideline establishes a definition of a surrogate sample, provides recommendations for determining when to use surrogate samples, and describes a process for selecting the most appropriate surrogate sample.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

A Hierarchical Approach to Selecting Surrogate Samples for the Evaluation of *In Vitro* Medical Laboratory Tests

April Veoukas, BS, JD
Shannon Bennett, MS, MBA, CMQOE(ASQ)
Melissa Barhoover, PhD, RAC
Natalya Benina, MS
Marvin Berman, PhD
Marc D. Goldford, BS
Shiaolan Y. Ho, PhD
Mark D. Kellogg, PhD, MT(ASCP), DABCC, FAACC
Mary Knighten, MT(AMT)

Marina V. Kondratovich, PhD
Gregory Jay Pomper, MD
Paula Ladwig, MS, MT(ASCP)
Fred D. Lasky, PhD
Sangeetha Vijaysri Nair, DVM, PhD
Patrick O'Donnell, BA
Michael Pikulski, PhD, DABCC, FACC
Yvonne Shea, MS
Bin Zhang, MD, MS

Abstract

Clinical and Laboratory Standards Institute guideline EP39—*A Hierarchical Approach to Selecting Surrogate Samples for the Evaluation of In Vitro Medical Laboratory Tests* establishes a standard definition of a surrogate sample. It presents a hierarchical approach for determining when to use surrogate samples and selecting an appropriate one. It also describes elements of a surrogate sample plan and includes technical preparation guidance for the characteristic to be measured or detected and for artificial matrix compositions. This guideline provides examples for specific performance study types.

Clinical and Laboratory Standards Institute (CLSI). *A Hierarchical Approach to Selecting Surrogate Samples for the Evaluation of In Vitro Medical Laboratory Tests*. 1st ed. CLSI guideline EP39 (ISBN 978-1-68440-130-7 [Print]; ISBN 978-1-68440-131-4 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2021.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org.

If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:

P: +1.610.688.0100 **F:** +1.610.688.0700 **E:** customerservice@cls.org **W:** www.clsi.org

Copyright ©2021 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. *A Hierarchical Approach to Selecting Surrogate Samples for the Evaluation of In Vitro Medical Laboratory Tests*. 1st ed. CLSI guideline EP39. Clinical and Laboratory Standards Institute; 2021.

Reaffirmed:
October 2025

Sample

EP39-Ed1

ISBN 978-1-68440-130-7 (Print)

ISBN 978-1-68440-131-4 (Electronic)

ISSN 1558-6502 (Print)

ISSN 2162-2914 (Electronic)

Volume 41, Number 21

Contents

Abstract	i
Committee Membership	iii
Foreword	vii
Chapter 1: Introduction	1
1.1 Scope	2
1.2 Background	2
1.3 Standard Precautions	3
1.4 Terminology	3
Chapter 2: Path of Workflow	9
Chapter 3: Samples	13
3.1 Patient Sample	14
3.2 Surrogate Sample	14
Chapter 4: Surrogate Sample Hierarchical Approach	17
4.1 Decision to Use Surrogate Samples	18
4.2 Surrogate Sample Hierarchy	18
4.3 Surrogate Sample Composition	19
Chapter 5: Surrogate Sample Plan	23
5.1 Identifying Needed Samples	25
5.2 Developing a Surrogate Sample Plan	26
Chapter 6: Technical Preparation Techniques	27
6.1 Overview	28
6.2 Determining the Analyte	28
6.3 Selecting the Matrix	30
6.4 Surrogate Sample Stability	30
6.5 Process Steps	31
6.6 Storage	31

Contents (Continued)

Chapter 7: Special Considerations	33
7.1 Qualifying the Surrogate Sample	34
7.2 Demonstrating Comparability	35
7.3 Using Surrogate Samples for More Than One Study	36
7.4 Preparing Blank Surrogate Samples	37
7.5 Creating a Single Signature Score From Multiple Genes	39
7.6 Rare Subtypes	40
7.7 Surrogate Samples for Molecular Assays	41
Chapter 8: Application to Performance Studies	43
8.1 Linearity	44
8.2 Analytical Specificity	46
8.3 Precision	48
8.4 Detection Capability	49
8.5 Matrix Comparison	52
8.6 Method Comparison	54
8.7 Hook Effect	58
8.8 Sample Stability	59
8.9 Carryover	61
8.10 Reagent Stability	62
Chapter 9: Conclusion	65
Chapter 10: Supplemental Information	67
References	68
Additional Resources	72
Appendix A . Surrogate Sample Descriptions and Examples	73
Appendix B . Example Chemical Compositions for Artificial Matrixes	76
Appendix C . <i>Chlamydia trachomatis</i> : Precision/Reproducibility	79
Appendix D . Creatinine: Precision/Reproducibility	101
Appendix E . Total Prostate Specific Antigen: Precision/Reproducibility	106
Appendix F . Albumin: Method Comparison	112
Appendix G . <i>Chlamydia trachomatis</i> : Instrument Carryover	117
The Quality Management System Approach	128
Related CLSI Reference Materials	129

Foreword

Terms such as “contrived,” “altered,” “processed,” “diluted,” “supplemented,” and “simulated” have been used interchangeably to describe substitutions for patient samples. This guideline establishes a uniform term, “surrogate sample,” and definition to describe material(s) that is used as a substitute for body fluid or tissue from a single human individual.

When appropriately characterized patient samples are unavailable, surrogate samples serve an important role in the development, validation, and verification of laboratory tests. Surrogate samples may be needed for many reasons, including limited sample volume or inadequate numbers of patient samples with concentrations at medical decision levels or at the extremes of the analytical measuring interval. A lack of available patient samples may be due to low disease prevalence, invasive sampling methods, or other reasons.

This guideline establishes an approach for selecting, preparing, and using surrogate samples. It describes the principles for creating a surrogate sample plan and presents a hierarchy, by performance study type, for selecting an appropriate surrogate sample. The hierarchical approach is demonstrated through product- and performance-specific examples.

KEY WORDS

Artificial analyte

Artificial matrix

Hierarchy

Pooled

Sample plan

Simulated

Supplemented

Surrogate sample

Chapter 1

Introduction

This chapter includes:

- Guideline's scope and applicable exclusions
- Background information pertinent to the guideline's content
- Standard precautions information
- Terminology information, including:
 - Terms and definitions used in the guideline
 - Abbreviations and acronyms used in the guideline

A Hierarchical Approach to Selecting Surrogate Samples for the Evaluation of *In Vitro* Medical Laboratory Tests

1 Introduction

1.1 Scope

This guideline establishes a definition of “surrogate sample” and an approach for selecting, preparing, and using these samples. It discusses surrogate sample:

- Composition
- Technical preparation
- Selection criteria
- Documentation and planning
- Use in specific performance study types

The intended users of this guideline are *in vitro* diagnostic (IVD) device developers, laboratorians, and regulators. This guideline does not describe performance study design, which is covered in other standards and guidelines (see CLSI document EP19³).

1.2 Background

Development, validation, and verification of laboratory tests depends on the availability of patient samples for testing. When appropriate patient samples are unavailable to validate test performance, using surrogate samples enables more efficient use of biological materials, improves testing efficiency, and facilitates the development of tests for new biomarkers. Patient samples for test development and other uses may be unavailable for several reasons.

Reasons that patient samples cannot be used include:

- Logistical constraints
- Insufficient sample volumes
- Inadequate numbers of samples, such as those with concentrations at medical decision levels (MDLs) or at the extremes of the analytical measuring interval (AMI)
- Technical constraints
- Unsatisfactory samples (ie, that lack the necessary characteristics for a performance study)
- Instability of samples
- Unavailability of blank or negative samples

Sample



CLINICAL AND
LABORATORY
STANDARDS
INSTITUTE®

PRINT ISBN 978-1-68440-130-7
ELECTRONIC ISBN 978-1-68440-131-4

EP39-Ed1